New Male Contraceptive Drug Passes Initial Human Testing

A promising new contraceptive for men has just completed its first human trials. Preliminary results indicate that this drug, which operates without synthetic hormones and does not interfere with testosterone levels from the testes, appears to be safe for human use.

Historically, attempts to create a male contraceptive have largely faltered in clinical trials, often due to adverse side effects that were considered unacceptable.

However, this latest contraceptive employs a different approach, eliminating the need for surgery and minimizing the likelihood of hormonal side effects—a key factor that has hindered previous advances from succeeding in the market.

This study discovered that the drug was well received among a small group of healthy young men and that serious side effects were not evident at the tested doses. Further investigation will be vital to ascertain its effectiveness as a contraceptive.

The new method centers on a specifically engineered chemical called YCT-529, which targets a particular cell receptor in the testes known as retinoic acid receptor-alpha.

While similar compounds have previously been shown to diminish sperm production in men, they also brought along negative side effects such as nausea when consuming alcohol, fluctuating salt levels in the blood, and incomplete reversibility—all of which made them unsuitable for contraceptive use.

Animal studies revealed that YCT-529 effectively induced temporary, reversible infertility without significant adverse effects. A study conducted on mice showed that those that stopped taking the drug were still able to father healthy offspring.

Following these encouraging findings, the drug moved into phase 1 trials with human participants, a preliminary step focused on assessing safety, tolerability, and potential side effects using a small group of healthy volunteers.

This initial trial included 16 male volunteers who received the drug at escalating doses—either between 10mg to 30mg or 90mg to 180mg. Some participants took placebo pills for control.

Over a 15-day monitoring period, researchers looked for impacts on hormone levels, signs of inflammation, kidney and liver function, irregular heart rhythms, sexual drive, and mood.

No significant changes in natural hormone levels were detected, nor were any lasting effects on liver and kidney function or indications of cell damage. There were also no concerning heart rhythm changes reported, and the participants didn’t express shifts in mood or desire.

It’s important to note that these participants only took two doses and were monitored for a limited time. The researchers indicate in their report that a larger phase 2 trial is currently in the works, which will involve a broader array of male participants.

This will be succeeded by phase 3 trials involving hundreds of men, aimed at evaluating the drug’s effectiveness, reversibility, and side effects over extended use—challenges that past products have struggled to overcome.

Challenges Facing Past Male Contraceptives

At the moment, there aren’t any commercially available male contraceptive methods that are both safe and effective, allowing for easy control over sperm production.

Condoms have minimal side effects and flexible usage, but they come with a relatively high failure rate, resulting in unintended pregnancies about 12%-18% of the time when used typically.

A vasectomy is over 99% effective and safe, but it’s not easily reversible and necessitates a minor surgical procedure.

Past attempts—some ongoing—have explored reversible contraception methods for men. Although some showed promise in halting sperm production or preventing sperm from exiting the male reproductive system, they’ve mostly failed to reach the commercial stage, often due to unwanted side effects.

Most strategies have revolved around two main avenues. One involves injecting substances into the vas deferens, which leads from the testes to the urethra, effectively filtering out and harming sperm during ejaculation. While this can potentially be reversed with another minor procedure, it necessitates initial surgical intervention, which some may find off-putting.

The other strategy has aimed at stopping sperm production by lowering hormones responsible for it. This approach was more successful but involved using an injectable form of progestogen, which signaled the brain to cease producing hormones that stimulate sperm and testosterone production. However, this also inadvertently reduced testosterone levels, requiring men to supplement it with additional testosterone in other forms.

A significant trial testing this method was halted prematurely due to hormonal side effects like mood swings, acne, and fluctuations in sex drive.

There is still a journey ahead before the new drug can be widely accepted as a male contraceptive. Yet, it holds considerable promise, primarily due to its avoidance of disrupting hormonal balance and the fact that it can be taken orally, sidestepping more invasive methods altogether.